{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:10:50Z","timestamp":1790187050401,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.biopha.2020.111118","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:23:56Z","timestamp":1608153836000},"page":"111118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure"],"prefix":"10.1016","volume":"134","author":[{"given":"Hong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-4393","authenticated-orcid":false,"given":"Yutian","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2020.111118_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.biopha.2020.111118_bib0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hep.27795","article-title":"Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults","volume":"62","author":"Shi","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2020.111118_bib0015","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2020.111118_bib0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"9865","key":"10.1016\/j.biopha.2020.111118_bib0025","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2020.111118_bib0030","first-page":"17","article-title":"Antiviral therapy for hepatitis B virus associated hepatic failure","volume":"8","author":"Wang","year":"2009","journal-title":"HBPD Int."},{"issue":"9","key":"10.1016\/j.biopha.2020.111118_bib0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0040","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2020.111118_bib0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address, e.e.e. And L. European Association for the Study of the, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2020.111118_bib0050","first-page":"938","article-title":"[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]","volume":"27","author":"Chinese Society of Infectious Diseases","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"10.1016\/j.biopha.2020.111118_bib0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/jhep.2000.16333","article-title":"Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy","volume":"32","author":"Honkoop","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.51.4.597","article-title":"Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B","volume":"51","author":"Lim","year":"2002","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.biopha.2020.111118_bib0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/00365548.2012.704152","article-title":"Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases","volume":"45","author":"Wang","year":"2013","journal-title":"Scand. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2020.111118_bib0070","first-page":"369","article-title":"Fatal fulminant hepatitis B after withdrawal of entecavir treatment in a patient with HBeAg seroconversion","volume":"75","author":"Sarikaya","year":"2012","journal-title":"Acta Gastroenterol. Belg."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol. Int."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.biopha.2020.111118_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12985-016-0536-0","article-title":"Changing etiologies and outcome of liver failure in Southwest China","volume":"13","author":"Xie","year":"2016","journal-title":"Virol. J."},{"issue":"2","key":"10.1016\/j.biopha.2020.111118_bib0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/gastro\/gou075","article-title":"Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure","volume":"3","author":"Kumar","year":"2015","journal-title":"Gastroenterol. Rep. (Oxf)"},{"key":"10.1016\/j.biopha.2020.111118_bib0095","doi-asserted-by":"crossref","first-page":"5029789","DOI":"10.1155\/2018\/5029789","article-title":"Acute-on-Chronic liver failure: from basic research to clinical applications","volume":"2018","author":"Chen","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0100","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/jgh.12787","article-title":"Increased delayed mortality in patients with acute-on-chronic liver failure who have prior decompensation","volume":"30","author":"Shi","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/jgh.13213","article-title":"Acute on chronic liver failure because of acute hepatic insults: etiologies, course, extrahepatic organ failure and predictors of mortality","volume":"31","author":"Shalimar","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2020.111118_bib0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2020.111118_bib0115","doi-asserted-by":"crossref","first-page":"1433987","DOI":"10.1080\/16549716.2018.1433987","article-title":"Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B","volume":"11","author":"Xu","year":"2018","journal-title":"Glob. Health Action"},{"key":"10.1016\/j.biopha.2020.111118_bib0120","doi-asserted-by":"crossref","first-page":"25487","DOI":"10.1038\/srep25487","article-title":"Characteristics, diagnosis and prognosis of acute-on-Chronic liver failure in cirrhosis associated to hepatitis B","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2020.111118_bib0125","first-page":"252","article-title":"[Prognostic analysis of acute-on-chronic liver failure after withdrawal of nucleos(t)ide analogues for antiviral treatment of chronic hepatitis B]","volume":"24","author":"Ou","year":"2016","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"10.1016\/j.biopha.2020.111118_bib0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MEG.0000000000001574","article-title":"Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs","volume":"32","author":"Wang","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:01:22Z","timestamp":1760097682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220313111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"alternative-id":["S0753332220313111"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111118","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111118"}}